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Abstract
The clinical utility of estrogens for treating prostate
cancer (CaP) was established in the 1940s by Huggins.
The classic model of the anti-CaP activity of estrogens
postulates an indirect mechanism involving the sup-
pression of androgen production. However, clinical and
preclinical studies have shown that estrogens exert
growth-inhibitory effects on CaP under low-androgen
conditions, suggesting additional modes whereby
estrogens affect CaP cells and/or the microenviron-
ment. Here we have investigated the activity of 17B
estradiol (E2) against androgen-independent CaP and
identified molecular alterations in tumors exposed to
E2. E2 treatment inhibited the growth of all four
androgen-independent CaP xenografts studied (LuCaP
35V, LuCaP 23.1AI, LuCaP 49, and LuCaP 58) in cas-
trated male mice. The molecular basis of growth sup-
pression was studied by cDNA microarray analysis,
which indicated that multiple pathways are altered
by E2 treatment. Of particular interest are changes in
transcripts encoding proteins that mediate immune
responses and regulate androgen receptor signaling.
In conclusion, our data show that estrogens have
powerful inhibitory effects on CaP in vivo in androgen-
depleted environments and suggest novel mechanisms
of estrogen-mediated antitumor activity. These results
indicate that incorporating estrogens intoCaP treatment
protocols could enhance therapeutic efficacy even in
cases of advanced disease.
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Introduction
Despite substantial attention, the development of androgen-
independent prostate cancer (CaP) is not well understood.
Progression to an androgen-independent state represents
resistance to suppression of the primary signaling pathway
used to control recurrent CaP. Accordingly, an evaluation of
the activities and mechanisms of new therapeutics that
specifically target androgen-independent CaP growth is of
special therapeutic interest.
For some 30 years, estrogens, particularly diethylstilbestrol
(DES), were commonly used in the initial treatment of advanced
CaP [1–6]. Originally, it was believed that the responses of CaP
to estrogen therapy weremediated primarily by the suppression
of the hypothalamic–hypophyseal axis and the consequent
reduction in testosterone levels [7–10]. However, DES treat-
ment was associated with significant side effects, and the
Veterans Administration Cooperative Urological Research
Group (VACURG), in 1967, recommended that hormonal ther-
apy with DES be withheld until symptoms of metastatic disease
appeared and that administration of DES at a level of 5 mg/day
was associated with an excessive risk of cardiovascular mor-
tality [11,12]. In a further study, VACURGII compared various
dosages of DES and concluded that 1 mg/day is as effective as
5 mg/day in controlling T3 M+ CaP [13]. In 1988, however, even
this level of DES was found to be associated with a high risk
for cardiovascular problems, mainly in patients over 75 years
of age [14]. The use of DES in the treatment of CaP ended
with the advent of luteinizing hormone–releasing hormone
analogs, which are now mainly used as a means of chemi-
cal castration.
Nevertheless, published studies suggest that: 1) estro-
gens inhibited the growth of CaP by mechanisms unrelated
to androgen suppression; 2) patients treated with estrogen
appeared to have survived somewhat longer than patients
who had undergone surgical castration [3]; 3) administration of
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DES to patients with hormone-independent CaP suppressed
prostate-specific antigen (PSA) and prolonged survival more
effectively than administration of the antiandrogen flutamide
[15]; and 4) Byar and Corle [4] commented that no form of
endocrine therapy had been proven to be superior to 1 mg
of DES daily. The hypothesis of direct inhibitory effects of
estrogen on CaP is supported by observations that estrogen
receptors are expressed in normal and neoplastic prostate
epithelia [16–18], by observations that estrogens exhibit
direct cytotoxic effects on CaP cells in vitro [19–23], and
by our own demonstration of growth inhibition of CaP by
17b estradiol (E2) in the androgen-free environment of ovari-
ectomized female mice [24].
The discovery of a second estrogen receptor, estrogen
receptor b (ERb), renewed interest in basic research involving
estrogen pathways. Several reports have shown that ERb is
present in normal prostate epithelial cells as well as in CaP,
and levels of ERb messages and/or proteins appear to be
downregulated during disease progression [16–18,25]. A
straightforward hypothesis holds that ERb transduces a
growth-inhibitory effect of estrogen on CaP cells. In support
of this hypothesis, a lower rate of cancer-related deaths was
observed in CaP patients with ERb versus CaP patients
without ERb [26], and an estrogenic compound operating
through the ERb receptor suppressed the growth of DU145
CaP cells [22,23]. In contrast to decreasing levels of ERbwith
CaP progression, we have recently demonstrated that ERb
is expressed in a majority of CaP bone and soft-tissue
metastases [27], as in another report on ERb expression in
a small number of CaP metastases [16]. Together, these
studies suggest that estrogen action against prostate carci-
noma could involve ERb or potentially other direct modes of
action such that CaP growth may be restrained even in an
androgen-independent state.
The current study was undertaken to determine whether
estrogenic compounds can inhibit the growth of androgen-
independent CaP and to investigate phenotypic changes
associated with antitumor effects. Using human CaP xeno-
grafts, our results show that estrogenic compounds clearly
suppress androgen-independent growth of CaP in casthe
trated hosts, calling into question the traditional view that
estrogen’s activity against CaP depends solely on androgen
suppression. The results indicate that estrogens may be
especially useful in the treatment of androgen-independent
CaP. We identified several novel molecular alterations re-
sulting from tumor exposure to E2 that may contribute to
E2-mediated tumor inhibition. Further studies are warranted
to exploit the antitumor effects of E2 treatment in the con-
text of advanced CaP.
Materials and Methods
Animal Studies
Xenografts Androgen-sensitive PSA-producing CaP xeno-
grafts LuCaP 35 [28], LuCaP 23.1 [29,30], and LuCaP 58 [31]
(which all originated from lymph node metastases), and
androgen-insensitive neuroendocrine-type CaP xenograft
LuCaP 49 (which originated from omental fat metastasis)
[32] were used. The xenografts were maintained and pro-
pagated in Balb/c nu/nu intact male mice. The androgen-
independent variants of LuCaP 35V and LuCaP 23.1 were
developed from parental tumors on regrowth after castra-
tion [28,31] and were maintained and propagated in
castrated B17 Fox Chase SCID male mice (Charles River,
Wilmington, MA).
Effects of E2 on recurrent LuCaP 35 after castration All
animal procedures were performed in compliance with the
University of Washington Institutional Animal Care and Use
Committee and National Institutes of Health guidelines. In our
first study, LuCaP 35 tissue bits were implanted subcuta-
neously into SCID male mice. Tumor growth was monitored
by measuring tumor volume twice a week. Serum was
collected weekly for PSA determination. Animals were cas-
trated when the tumors reached 200 to 400 mm3. Animals
with recurrent tumors (determined as two rising serum PSA
values) were randomized into three groups of 10 animals
each. Group 1 animals received placebo pellets.
Group 2 animals were supplemented with E2 by the
subcutaneous implantation of slow-release Trocar pellets
(90-day-release E2, 100–125 pg/ml; Innovative Research
of America, Sarasota, FL), and group 3 animals were sup-
plemented with DES pellets by the subcutaneous implan-
tation of slow-release Trocar pellets (90-day-release DES,
0.01 mg; Innovative Research of America). Animals were
sacrificed when tumors exceeded 1000mm3 at 90 days post-
implantation or when the animals became compromised.
Student’s unpaired two-tailed t-test was used to analyze the
differences between groups.
Effects of E2 on LuCaP 35V in castrated male mice In ad-
ditional experiments performed to determine the effects of
E2 on proliferation and gene expression, we used the
androgen– independent xenograft LuCaP 35V [28]. SCID
male mice were castrated at 8 weeks of age and implanted
with LuCaP 35V tumor bits at least 2 weeks after surgery.
Tumor growth was monitored by tumor measurements
twice a week using calipers, and tumor volume was calcu-
lated as 0.5236LHW. Blood samples were collected weekly
for the determination of serum PSA levels (IMx Total PSA
Assay; Abbott Laboratories, Abbott Park, IL). When tumors
reached 200 to 400 mm3, the animals were randomized into
two groups. Group 1 was supplemented with E2 by the
subcutaneous implantation of slow-release Trocar pellets
(60-day release, 0.05 mg; Innovative Research of America).
Group 2, which received placebo pellets, was the control
group. Five animals from each group were sacrificed on days
1, 3, and 7 postimplantation of E2 pellets. One hour before
sacrifice, the animals were injected intraperitoneally with
80 mg/kg body weight 5-bromo-2-deoxyuridine (BrdU;
Sigma-Aldrich Co., St. Louis, MO) for evaluation of tumor
cell proliferation. Tumors were fixed in formalin and em-
bedded in paraffin. The 10 remaining animals in each
group were monitored for long-term assessment of tumor
growth and PSA production after E2 treatment. Animals
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were sacrificed when tumors exceeded 1000 mm3 at
60 days postimplantation or when the animals became com-
promised. Tumors were frozen in liquid nitrogen and stored at
80jC and/or fixed with formalin and embedded in paraffin,
and serum was collected for determination of E2 levels (IMx
Estradiol Immunoassay; Abbott Laboratories). Student’s un-
paired two-tailed t-test was used to analyze the differences
between groups, and a log-rank test was used to evaluate
differences in survival.
Effects of E2 on the growth of LuCaP 23.1AI, LuCaP 49,
and LuCaP 58 in castrated male mice To investigate
whether the E2 inhibition of androgen-independent growth
occurs with other CaP cells (not just LuCaP 35 lines), we
set up similar experiments with three additional xeno-
grafts: LuCaP 35AI, LuCaP 49, and LuCaP 58. The ex-
perimental design was the same as for the study with
LuCaP 35V. Tumor bits were implanted in castrated male
mice (aiming for n = 10 per group) at least 2 weeks after
surgery, and tumor growth and PSA levels were monitored.
Animals bearing each particular xenograft were randomized
into two groups (tumors 200–400 mm3). Group 1 was sup-
plemented with E2 by the subcutaneous implantation of
slow-release Trocar pellets (60-day release, 0.05 mg; Inno-
vative Research of America). Group 2, which received pla-
cebo pellets, was the control group. Animals were sacrificed
when tumors exceeded 1000 mm3 at 60 days postimplanta-
tion or when the animals became compromised. Tumors
were frozen in liquid nitrogen and stored at 80jC and/or
fixed with formalin and embedded in paraffin. Student’s
unpaired two-tailed t-test was used to analyze differences
between groups.
Proliferation and Apoptosis Assays
Samples of LuCaP 35V tumors treated with E2 for 1, 3,
and 7 days, and control tumors were fixed in formalin and
embedded in paraffin. An anti-BrdU immunohistochemistry
kit was used to assess the number of proliferating cells
(Zymed, San Francisco, CA). Five-micrometer sections of
paraffin-embedded tissues were used for the analysis, as
recommended by the manufacturer. Apoptosis in tumors
was assessed with a FragEL DNA fragmentation detection
kit from Oncogene (La Jolla, CA), as recommended by
the manufacturer. Positive nuclei or apoptotic cells were
counted in five representative fields containing f1000 cells
in three samples of treated and untreated tumors from
each time point. Statistical analysis was performed using
Student’s t test.
Cell Culture
Seven hundred to 900 mm3 of LuCaP 35V tumors grown
and passaged in castrated SCID mice were harvested
for the isolation of epithelial cells [28]. Isolated cells were
rinsed thrice and plated overnight in 10% charcoal-stripped
fetal bovine serum (Hyclone, Logan, UT) in phenol red-free
RPMI 1640 (Invitrogen, Carlsbad, CA). LuCaP 35V cells
were treated with 108 M E2 or vehicle (0.01% EtOH) for
4 hours.
Western Blot Analysis
Following treatment with E2 or vehicle, nuclear and cyto-
plasmic fractions were prepared as previously published [33].
Proteins (25 mg/well) were separated by 12.5% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membrane (PVDF)
membranes. Blots were blocked in a 1:1 solution of NaP-Sure
blocker (Geno Technology, Inc., St. Louis, MO) and Tris-
buffered saline + 0.1% Tween-20 for 2 hours, then probed
with a rabbit polyclonal antibody against ERb (Affinity BioRe-
agents, Golden, CO) for 1 hour at room temperature. ERb
immunoreactivity was detected using a goat anti– rabbit
secondary antibody conjugated with horseradish peroxidase
(1:2000; Amersham, Piscataway, NJ). Blots were developed
using the Amersham ECL.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts fromLuCaP35V treatedwith 108ME2or
vehicle (0.01% EtOH) for 4 hours (25 mg) were incubated with
50 fmol of dsDNA probes for 30 minutes at 37jC in a buffer
containing: 20 mM Tris (pH 8), 10 mM NaCl, 3 mM EDTA,
0.05% Nonidet P-40, 2 mM DTT, 4% glycerol, 1 mM MgCl2,
and 1 mg of poly dI–dC (Amersham). The binding consensus
sequences used were an estrogen response element (ERE;
GGATCTAGGTCACTGTGACCCCGGATC) and a mutated
form of ERE (GGATCTAGTACACTGTGACCCCGGATC;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Double-
stranded DNA were end-labeled with [g-32P]ATP (Amersham)
using T4 polynucleotide kinase (Promega, Madison, WI). For
competition studies, 50 fmol of unlabeled probe was added
to the reaction. Protein–DNA complexes were separated
in 4% nondenaturing polyacrylamide gels.
RNA Isolation
Tumors from animals treated with E2 for 60 days and
control tumors were homogenized using an Omni TH ho-
mogenizer (Omni International, Warrenton, VA), and RNA
was extracted using TriPure Isolation Reagent (Roche, Indi-
anapolis, IN), according to the manufacturer’s instructions.
RNA quantity was determined based on A260, and the integ-
rity of RNA was confirmed by agarose gel.
cDNA Array Analysis
PEDB cDNA microarrays containingf7000 human pros-
tate–derived cDNA clones were prepared on poly-L-lysine–
coated glass microscope slides using a robotic spotting tool,
as previously described [34–36]. Equal amounts of total RNA
from five tumors of LuCaP 35V (control) and E2-treated
LuCaP 35V (treatment) were pooled, and cDNA array experi-
ments and analysis were performed as previously described
[37]. For individual experiments, every cDNA was repre-
sented twice on each slide, and the experiments were per-
formed in triplicate with a switch in fluorescent labels to
account for dye effects, producing six data points per cDNA
clone per hybridization probe. Data were filtered to exclude
poor-quality spots, were normalized, and included clones
whose expression was measurable in at least two of three
arrays, reducing the initial list of 6720 clones to 5163 clones.
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Gene Expression Analysis
To compare the overall expression patterns of replicate
LuCaP 35V (control) and E2-treated LuCaP 35V (treatment)
arrays, log2 ratio measurements were analyzed using the
SAM procedure [38] (http://www-stat.stanford.edu/_tibs/
SAM/). A one-sample t-test was used to determine whether
the mean gene expression of E2-treated LuCaP 35V versus
LuCaP 35V (control) differed significantly from zero. A false
discovery rate (FDR) of < 1% was considered significant.
Clones differentially expressed with an FDR < 1% were
stratified based on fold change, and we chose to further
evaluate only those with an average log2 (E2-treated/control)
> 0.58 or < 0.58, corresponding to a differential expression
effect of 1.5-fold or greater. We assigned differentially
expressed genes to the following functional categories based
on their annotations in the Gene Ontology database [39]:
metabolism, immune/inflammatory response, proliferation/
differentiation/apoptosis, signal transduction, structure/
adhesion/motility, transcription regulation, translation protein
synthesis, transport, or other/unknown.
To determine whether phenotypic changes observed in
E2-treated tumors were enriched for genes in certain path-
ways, cDNA array results were subjected to Gene Set En-
richment Analysis (GSEA) [40]. For this analysis, interferon
(IFN)–regulated, androgen-regulated, and estrogen-regulated
gene sets were tested against our data. IFN-regulated and
estrogen-regulated gene sets were generated from Super-
Array Bioscience Corporation GEArray pathway-focused
gene lists (http://www.superarray.com), and the androgen-
regulated gene set was generated based on the results of
DePrimo et al. [41]. To assess the statistical significance of
the enrichment score observed in the data set for the three
gene sets, we used permutation testing of phenotype labels
(e.g., E2-treated versus controls), generating a nominal
(NOM) P value. An FDR statistic was computed to adjust
for gene set size andmultiple hypothesis testing, with an FDR
of < 25% considered significant.
Quantitative reverse transcription–polymerase chain reac-
tion (qRT-PCR) First-strand cDNA synthesis was per-
formed with 1.0 mg of pooled RNA from five animals of the
E2 and control groups using oligo-dT18 primers according to
the manufacturer’s instructions (Clontech, Palo Alto, CA).
Real-time PCR was carried out on cDNA samples using
Platinum Quantitative PCR SuperMix-UDG reagent (Invi-
trogen) and performed on a Rotor-Gene 2000 (Corbett Re-
search, New South Wales, Australia). PCR primers were
designed to span an intron–exon boundary and to avoid
amplification of any known pseudogene. Primers for the
messages evaluated are listed in Table 1. Two microliters
of cDNA was used per reaction with 200 nM primers, 0.5
Syber Green 1 (Molecular Probes, Eugene, OR), and
5.5 mM MgCl2. The PCR reaction parameters were as
follows: 50jC for 2 minutes and 95jC for 2 minutes (one
cycle), followed by 35 cycles at 95jC for 10 seconds and
annealing/extension at either 65jC or 69jC for 30 seconds;
Table 1. Primer Sequences.
Abbreviation Name Primer Sequence Position Annealing
Temperature (jC)
Size (bp) Accession
Number
GAPDH Glyceraldehyde
dehydrogenase
5V TGC ACC ACC AAC TGC TTA GC 556 575 65 86 NM_002046
3V GGC ATG GAC TGT GGT CAT GAG 642 622
EGP Epithelial glycoprotein 5V GCT GGA ATT GTT GTG CTG GTT ATT TC 1019 1044 65 152 NM_002354
3V TGT GTC CAT TTG CTA TTT CCC TTC TTC 1171 1145
CD74 CD74 antigen (invariant
polypeptide, MHC class II
antigen–associated)
5V GTG CGA CGA GAA CGG CAA CTA TC 704 726 69 218 NM_001025159
3V GAA GAC CGC CTC TGC TGC TCT C 901 922
HLA II DRA MHC class II DR a 5V CCC AGA GAC TAC AGA GAA CGT GG 714 736 69 265 NM_019111
3V GGG CTG GAA AAT GCT GAA GAT GAC 979 956
HLA 1F MHC class I F 5V GTT GCC CAC CAC CCC ATC TCT G 628 649 65 371 NM_018950
3V GCT CTT CTT CCT CCA CAT CAC AG 977 999
IFITM1 IFN-induced transmembrane
protein 3 (1–8 U)
5V CGT CGC CAA CCA TCT TCC TGT C 530 509 69 246 NM_003641
3V TTC ACT CAA CAC TTC CTT CCC CAA 284 307
HLA DQB1 MHC class II DQ b1 5V GCC TTA TCA TCC ATC ACA GGA GTC 797 820 65 223 NM_002123
3V GTC ACA GCC ATC CGC CTC AAG G 999 1020
IFITM3 IFN-induced transmembrane
protein 3 (1–8 U)
5V GTC CAA ACC TTC TTC TCT CCT GTC 250 273 69 264 NM_021034
3V CGT CGC CAA CCA TCT TCC TGT C 514 493
BST2 Bone marrow stromal
cell antigen 2
5V GAG GTG GAG CGA CTG AGA AGA GA 406 428 69 204 NM_004335
3V GTT CAA GCG AAA AGC CGA GCA GG 610 588
b2M b2-Microglobulin 5V GAG TAT GCC TGC CGT GTG AAC CA 349 371 69 313 NM_004048
3V ACC TCT AAG TTG CCA GCC CTC CT 640 662
CD59 CD59 antigen p18–20 5V CTG CTG CTC GTC CTG GCT GTC T 149 170 69 370 NM_000611
3V GCT CTC CTG GTG TTG ACT TAG GG 497 519
IFIT1 IFN-induced protein with
tetratricopeptide repeat 1
5V CTG AAA ATC CAC AAG ACA GAA TAG C 5 29 69 377 NM_001001887
3V GTC ACC AGA CTC CTC ACA TTT GCT 359 382
IRF1 IFN-regulatory factor 1 5V GTA CCG GAT GCT TCC ACC TCT CAC C 524 545 69 105 NM_002198
3V GCT GGA ATC CCC ACA TGA CTT CCT C 605 629
IFI27 IFNa-inducible protein 27 5V GTT GTG ATT GGA GGA GTT GTG G 226 247 65 193 NM_005532
3V GAG AGT CCA GTT GCT CCC AGT 399 419
ERb Estrogen receptor b 5V GCT AAC CTC CTG ATG CTC CTG TCC 1784 1807 65 204 NM_001437
3V AGC CCT CTT TGC TTT TAC TGT CCT CT 1988 1963
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the final extension was 72jC for 7 minutes. PCR reaction
products were confirmed by agarose gel electrophoresis.
Standard curves for each amplicon were generated from a
four-fold dilution series of LNCaP cDNA run in duplicate (all
standard curves had r > 0.99). Reactions were carried out in
duplicate, and expression levels were calculated from a
standard curve.
Normalization strategy The normalization scheme ap-
plied to real-time PCR results was based on the method of
Vandesompele et al. [42]. This method employs multiple
internal control genes to identify the most stably expressed
control genes in samples of interest. The following mes-
sages were evaluated for use as internal controls: epithelial
glycoprotein (EGP), glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), hydroxymethylbilane synthase (HMBS), hypo-
xanthine phosphoribosyltransferase 1 (HPRT1), and
proteasome (prosome,macropain) subunit, b type, 6 (PSMB6).
Real-timePCRon pooled samples was performed in duplicate,
and expression levels were calculated based on standard
curves, as above. The average expression levels were
imported into the geNorm program (http://allserv.rug.ac.be/
fjvdesomp/genorm/) to determine the two most stably
expressed internal control genes. Briefly, geNorm determines
the gene stability measureM as the average pairwise variation
between a particular internal control gene and all other control
genes. The stepwise exclusion of endogenous control genes
with the highest M values resulted in the selection of GAPDH
and EGP as the most stably expressed control genes. The
normalization of the real-time PCR data of the gene of interest
was accomplished by dividing raw expression levels by the
geometric mean of the most stable endogenous control.
Results
Inhibition of Androgen-Independent CaP by E2 and DES
LuCaP 35 is an androgen-sensitive CaP xenograft,
expressing PSA and wild-type androgen receptors (ARs),
which recapitulates a response to androgen ablation and the
development of androgen-independent CaP similar to that
observed in humans [28]. Its growth in intact female mice is
suppressed in comparison to that in ovariectomized female
mice [24]. Therefore, we have chosen this xenograft for
initial evaluation of the effects of estrogenic compounds in
male mice. Surgical castration of intact male mice bearing
LuCaP 35 CaP xenografts resulted in a reproducible time-
dependent reduction in tumor volume and PSA serum levels.
Recapitulating human disease, 88% of the tumors eventually
recurred in the androgen-depleted environment, with a range
in time to recurrence of 32 to 91 days (median = 61.5 days;
Figure 1, A and B). Tumor recurrence was defined as two
consecutive rising values of serum PSA. Without treatment,
these androgen-independent tumors continued to grow
and reached a size of f1000 mm3 by days 24 to 31 post-
castration. Administration of E2 or DES inhibited the growth
of recurrent LuCaP 35 tumors; at 104 days after castration,
the tumor volumes were 134.3 ± 16.4 mm3 (mean ± SEM) for
E2 (with PSA levels of 1.82 ± 0.66 ng/ml) and 49.8 ± 12.1mm3
for DES (with PSA levels of 3.20 ± 1.86 ng/ml). Tumor
volumes and PSA levels decreased, and none of the tumors
reached an estrogen-resistant state during the course of the
study (90 days of treatment). PSA values closely followed
tumor volume. Three animals from the E2-treated and DES-
treated groups were monitored for an additional 60 days after
expiration of the estrogen pellets. Tumor volumes and PSA
serum levels in these animals started to increase during this
period (Figure 1). The tumors in animals that were treated
with E2 reached 587.6 ± 194.0 mm3 (P = .0008 from 90 days
Figure 1. Effects of estradiol on the recurrent growth of LuCaP 35 CaP
xenografts. LuCaP 35 tumor bits were implanted in intact animals, and animals
were castrated when tumors reachedf200 to 400 mm3. Tumor volume was
measured twice a week. Blood was drawn weekly for the determination of PSA
serum levels. On the development of recurrent CaP, as determined by two
subsequently increased PSA serum levels, animals were randomized into
three groups. E2 and DES pellets were implanted in treatment animals; control
animals received placebo pellets. Animals were sacrificed after tumors had
reached 1000 mg or 90 days postimplantation of the pellets. Three tumors
from E2-treated and DES-treated animals were monitored for an additional
670 days after pellet expiration. Data were synchronized with pellet
implantation, and results are presented as mean ± SEM. (A) Tumor volume.
(B) Serum PSA levels.
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after pellet expiration), with concordant rises in PSA serum
levels to 55.33 ± 21.18 (P = .003; to the levels when pellets
expired). Tumors in DES-treated animals started to increase
in volume more slowly than E2-treated tumors after pellet
expiration; the tumor volumes increased 1.5-fold (79.43 ±
32.5mm3) but did not reach significance (P= .3075), andPSA
serum levels began to rise (17.23 ± 11.20 ng/ml; P = .0533).
As observed in our previous study in female mice, adminis-
tration of E2 inhibited the growth of androgen-independent
LuCaP 35V xenografts in castrated male mice as well. The
tumor volume of LuCaP 35V–bearing animals treated with
E2 increased minimally over the original volume during the
60-day treatment period (Figure 2A). However, the tumor size
of LuCaP 35V in the control group increased from the time of
enrollment up to the time of sacrifice (days 25–35; tumor
volume = 1000 mm3; Figure 2A) (on day 32, P < .0001). PSA
serum levels closely paralleled tumor volumes (on day 28,
P = .0021) (Figure 2B). Levels of E2 in the control group of
castrated animals with LuCaP 35V (untreated) were below
the limit of assay detection (< 25 pg/ml). The level of E2 at
the time of sacrifice (60 days postimplantation of E2 pellets)
was 127.1 ± 22.5 pg/ml in treated LuCaP 35V animals.
Survival analysis, using tumor size (z 1000 mm3) as a death
criterion, showed that E2 dramatically prolonged the survival
of LuCaP 35V–bearing animals, as determined by log-rank
test (P < .0001; Figure 2C).
Generalized Growth-Inhibitory Effects of E2
on Androgen-Insensitive CaP
The growth of the three additional CaP xenografts LuCaP
23.1AI, LuCaP 49, and LuCaP 58 in an androgen-free
environment was inhibited by E2 administration to varying
degrees (Figure 3). The tumor volume of LuCaP 23.1AI
treated with E2 decreased, with significant differences from
untreated tumors after 7 days of treatment (P = .00089),
resulting in the near-disappearance of the tumors by day 35.
PSA serum levels closely followed the tumor volume. LuCaP
58 growth was also inhibited by E2 treatment, but to a lesser
extent; the tumor volume increased minimally over the orig-
inal volume during the 60-day treatment period (Figure 2A),
reaching significant inhibition versus untreated tumors on
day 7 (P = .0137). LuCaP 49, a neuroendocrine CaP xeno-
graft in which ARs are absent, was also inhibited by E2
administration, but the pattern of inhibition was different
from those of the other three xenografts. No significant
inhibition was observed for the first 10 days of treatment, after
Figure 2. Effects of estradiol on LuCaP 35V. LuCaP 35V, an androgen-insensitive CaP xenograft, was grown in castrated male SCID mice. When tumors reached
200 to 400 mm3, animals were supplemented with 60-day-release E2 pellets, as described in Materials and Methods section. Data are presented as mean ± SEM.
E2 inhibited the growth of androgen-independent LuCaP 35V in castrated male mice and caused significant increases in the survival of treated animals. PSA levels
closely followed the tumor volume. (A) Tumor volume. (B) Serum PSA levels. (C) Survival. (D) Proliferation. E2 treatment decreased the proliferation of LuCaP 35V
on days 3 and 7 of treatment. LuCaP 35V grown in castrated male mice was treated with E2 for 1, 3, or 7 days. BrdU staining was used to detect proliferating cells.
The percentage of positive nuclei was calculated based on the counts of stained nuclei in five representative fields containingf1000 cells from three samples of
treated and untreated tumors from each time point. Data are presented as mean ± SEM. Statistical analysis was performed using Student’s t test.
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which significant inhibition was reached (14 days, P = .0289).
E2-treated LuCaP 49 tumors continued growing, but at a
rate slower than that of untreated tumors.
Effects of E2 on Tumor Cell Proliferation and Apoptosis
To evaluate the mechanisms mediating LuCaP 35V tumor
reduction after E2 treatment, we measured the incorporation
of BrdU in untreated LuCaP 35V tumors versus tumors
from mice that received E2 for 1, 3, and 7 days. The number
of proliferating tumor cells decreased to 82.7 ± 7.3% of un-
treated tumors after 1 day (mean ± SEM), to 65.7 ± 4.2%
(P = .0063) after 3 days, and to 65.4 ± 10.1% (P = .0105)
after 7 days of E2 treatment (Figure 3). The rate of apoptosis
in E2-treated and untreated tumors, as measured by the
terminal deoxynucleotidyl transferase (TdT) FragEL DNA
fragmentation detection, was not significantly different (data
not shown).
Determination of E2-Mediated Alterations in Tumor
Gene Expression by Microarray Analysis
Comparative analyses of cDNA microarray gene expres-
sion profiles derived from LuCaP 35V xenografts treated
with E2 and untreated controls identified 300 cDNA whose
expression levels were significantly associated with E2 treat-
ment (FDR < 1%) and exhibited a > 1.5-fold difference in
expression level. Consolidation of redundant clones resulted
in 233 unique genes, of which 129 were downregulated and
104 were upregulated following E2 treatment (Tables 2
Figure 3. Effects of E2 treatment on the growth of CaP xenografts in an androgen-free environment. LuCaP 23.1, LuCaP 49, and LuCaP 58 were implanted in
castrated male mice. When tumors reached 200 to 400 mm3, the animals were divided into two groups per xenograft: 1) placebo and 2) E2 pellet. Tumor growth
and PSA were monitored as described in Materials and Methods section. Supplementation of E2 inhibited the growth of all three xenografts. (A) Tumor volume. (B)
PSA serum levels.
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Table 2. Genes Upregulated in E2-Treated LuCaP 35V versus Untreated LuCaP 35V.
Human Genome
Organization Gene
Name GenBank Entrez Gene Average
Fold D
Gene List
Metabolism
Carbohydrate
Lyzs Lysozyme (Mus musculus) M21050 17105 2.9
SIAT1 Sialyltransferase 1 NM_173217 6480 2.7
EXT1 Exostoses 1 BQ021387 2131 1.8
Lipid/sterol
UGT2B15 UDP glycosyltransferase 2 family, polypeptide B15 AF180322 7366 3.7
SORL1 Sortilin-related receptor, L (DLR class) A repeats–
containing
AK096577 6653 2.4
PSAP Prosaposin CR617297 5660 1.9
APOE Apolipoprotein E BG715607 348 1.8
CLN2 Ceroid lipofuscinosis, neuronal 2, late infantile AF017456 1200 1.8
Protein
FOLH1 Folate hydrolase (prostate-specific membrane antigen) 1 BC025672 2346 3.6
SQSTM1 Sequestosome 1 BQ220165 8878 1.8
DDC Dopa decarboxylase CA488364 1644 1.8
MAOA Monoamine oxidase A NM_000240 4128 1.5
Other
SOD2 Superoxide dismutase 2, mitochondrial BU527631 6648 1.9
VKORC1 Vitamin K epoxide reductase complex, subunit 1 NM_024006 79001 1.7
TBC1D14 TBC1 domain family, member 14 AL833868 57533 1.5
Immune response
CD74 CD74 antigen CA437013 972 5.1
HLA DRA MHC, class II, DR a BG757515 3122 3.4
HLA F MHC, class I, F AK096962 3134 3.0
LGALS3BP Lectin, galactoside-binding, soluble, 3–binding protein BQ883924 3959 2.6
HLA DQB1 MHC, class II, DQ b1 L34104 3119 2.5
HLA C MHC, class I, C X67818 3107 2.4
HLA B MHC, class I, B AK124160 3106 2.3 IFN
HLA A MHC, class I, A AK027084 3105 2.2 IFN
IFITM3 IFN-induced transmembrane protein 3 BQ441207 10410 2.1
BST2 Bone marrow stromal cell antigen 2 BQ053580 684 2.0 IFN
2M b2-Microglobulin BM453762 567 1.9 AR, IFN
CD59 CD59 antigen p18–20 BM550387 966 1.8
IFIT1 IFN-induced protein with tetratricopeptide repeats 1 BI670242 3434 1.8 IFN
IRF1 IFN-regulatory factor 1 CR594837 3659 1.8 IFN
IFI27 IFNa-inducible protein 27 BM998410 3429 1.5 IFN
Proliferation/differentiation/apoptosis
NDRG4 NDRG family member 4 AB021172 65009 2.8
BCCIP BRCA2 and CDKN1A-interacting protein BQ421346 56647 1.7
BIRC3 Baculoviral IAP repeat –containing 3 BC037420 330 1.7 AR
TMBIM1 Transmembrane BAX inhibitor motif – containing 1 AK130380 64114 1.6
AGR2 Anterior gradient 2 homolog BQ685832 10551 1.6 AR
UNC13B Unc-13 homolog B NM_006377 10497 1.6
TM4SF13 Transmembrane 4 superfamily member 13 AK093487 27075 1.6
NPM1 Nucleophosmin CN404150 4869 1.6
NDRG1 N-myc downstream– regulated gene 1 CR600627 10397 1.5 AR
KIAA0971 KIAA0971 protein CD671614 22868 1.5
Signal transduction
HSPA1A Heat shock 70 kDa protein 1A CR605852 3303 7.3
IFITM1 IFN-induced transmembrane protein 1 BQ219055 8519 2.8 IFN
LY6E Lymphocyte antigen 6 complex, locus E U42376 4061 2.2
STAT1 Signal transducer and activator of transcription 1, 91 kDa BG678000 6772 1.9 IFN
ARHGAP5 Rho GTPase-activating protein 5 BG260763 394 1.8
OGT O-linked N-acetylglucosamine (GlcNAc) transferase U77413 8473 1.7
RALGPS1A Ral guanine nucleotide exchange factor RalGPS1A AB002349 9649 1.6
FKBP4 FK506-binding protein 4, 59 kDa CD613711 2288 1.5
SH3KBP1 SH3 domain kinase–binding protein 1 AY423734 30011 1.5
NUDT4 Nudix-type motif 4 NM_019094 11163 1.5
Structure/adhesion/motility
MYLK Myosin, light polypeptide kinase BC062755 4638 3.9 AR
MYH3 Myosin, heavy polypeptide 3, skeletal muscle, embryonic CK824450 4621 1.8
SPARC Secreted protein, acidic, cysteine-rich (osteonectin) AL547671 6678 1.8
INA Internexin neuronal intermediate filament protein, a CR591335 9118 1.6
CLDN4 Claudin 4 BC000671 1364 1.5
LAMB2 Laminin, b2 AI754927 3913 1.5
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and 3). E2 treatment resulted in significant increases in the
expression of several genes that are involved in immune
responses (Table 2). These include major histocompatibility
complex (MHC) class I/II proteins, IFN-induced transmem-
brane protein 1 (IFITM1), IFN-induced transmembrane pro-
tein 3 (IFITM3), IFN-induced protein with tetratricopeptide
repeats 1 (IFIT1), IFNa-inducible protein 27 (IFI27), and IFN-
regulatory factor 1 (IRF1).
We have used GSEA to evaluate whether phenotypic
changes caused by E2 treatment in LuCaP 35V were as-
sociated with enrichment for IFN-regulated, androgen-
regulated, and estrogen-regulated genes. Our analysis
showed a significant enrichment of IFN-regulated genes
in E2-treated LuCaP 35V tumors (NOM P < .001), which
remained significant when adjusted for gene set size and
multiple hypothesis testing (FDR = 11.0%) (Figure 4A).
Significant enrichment was also detected when the andro-
gen deprivation–downregulated gene set was compared to
our results (NOM P < .001); this enrichment also remained
significant when adjusted for gene set size and multiple
hypothesis testing (FDR = 21.3%) (Figure 4B). Estrogen-
regulated genes were also enriched in phenotypic altera-
tions after E2 treatment (NOM P < .001); however, these
changes were not significant when adjusted for gene set
size and multiple hypothesis testing (FDR = 54.5%). We
hypothesize that this is due to the fact that changes in the
expression of these genes occur in both up and down
directions, and also due to inclusion in the list of genes that
are altered in breast cancer, which may not be relevant to
this study (Figure 4C).
Table 2. (continued )
Human Genome
Organization Gene
Name GenBank Entrez Gene Average
Fold D
Gene List
Transcription regulation
ID1 Inhibitor of DNA-binding 1, dominant-negative
helix – loop–helix protein
BM973065 3397 2.7
HIST1H2AC Histone 1, H2ac BC050602 8334 2.3
PMF1 Polyamine-modulated factor 1 BC050735 11243 2.0
NONO Non-POU domain–containing, octamer binding BG171743 4841 1.9
ZNFX1 Zinc finger, NFX1 type–containing 1 AB037825 57169 1.7
NFAT5 Nuclear factor of activated T-cells 5, tonicity-responsive NM_006599 10725 1.7
NOLC1 Nucleolar and coiled-body phosphoprotein 1 BE908347 9221 1.7
TRIM22 Tripartite motif – containing 22 AW080955 10346 1.7 AR, IFN
GPBP1 GC-rich promoter –binding protein 1 AL161991 65056 1.6
ADAR Adenosine deaminase, RNA-specific U18121 103 1.5 IFN
Translation–protein synthesis
HSP90AA2 Heat shock protein 90 kDa a, class A member 2 BC001695 3324 2.1
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 BC002352 3337 1.9
GOLPH4 Golgi phosphoprotein 4 AA447271 27333 1.8
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 BQ221194 3301 1.8
EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2 BT009860 1974 1.7
RPL23AP7 Ribosomal protein L23a pseudogene 7 X92108 118433 1.6
UBC Ubiquitin C AK129749 7316 1.5 AR
Transport
SELENBP1 Selenium-binding protein 1 BC009084 8991 2.9
APBA2 Amyloid b (A4) precursor protein–binding,
family A, member 2
BC082986 321 2.6
FLJ39822 Hypothetical protein FLJ39822 CA390853 151258 2.0
SLC12A2 Solute carrier family 12, member 2 AF439152 6558 2.0
FLJ39822 Hypothetical protein FLJ39822 AC019197 151258 1.9
C6orf29 Chromosome 6 open reading frame 29 AY358457 80736 1.9
ATP1B1 ATPase, Na+/K+ transporting, b1 polypeptide NM_001677 481 1.7
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A BC012169 523 1.7
FLJ10618 Hypothetical protein FLJ10618 AL049246 55186 1.5
NPC2 Niemann-Pick disease, type C2 CR608935 10577 1.5
NAPA N-ethylmaleimide–sensitive factor attachment protein, a BC007432 8775 1.5
ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 BI491181 10159 1.5
SLC25A26 Solute carrier family 25, member 26 AJ580932 115286 1.5
Other/unknown
MUC13 Mucin 13, epithelial transmembrane AK000070 56667 3.9
SAMD9L Sterile a motif domain–containing 9– like BC038974 219285 3.8
Transcribed locus CD103928 2.8
Transcribed locus, strongly similar to XP_496055.1
(predicted: similar to p40)
AW452111 2.3
C1orf43 Chromosome 1 open reading frame 43 BQ900746 25912 1.9
C1orf80 Chromosome 1 open reading frame 80 BC015535 64853 1.8
SERINC3 Serine incorporator 3 BI518460 10955 1.8
FAM73A Family with sequence similarity 73, member A AU131144 374986 1.6
ITM2B Integral membrane protein 2B CR745752 9445 1.6
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Table 3. Genes Downregulated in E2-Treated LuCaP 35V Versus Untreated LuCaP 35V.
Human Genome
Organization Gene
Name GenBank Entrez Gene Average
Fold D
Gene List
Metabolism
Carbohydrate
UGDH UDP glucose dehydrogenase BC022781 7358 2.0
GALNT7 UDP N-acetyl-a-D-galactosamine BM976847 51809 1.8
GPI Glucose phosphate isomerase AI124792 2821 1.8
RPN1 Ribophorin I CD644128 6184 1.8 AR
SORD Sorbitol dehydrogenase BC025295 6652 1.6 AR
GRHPR Glyoxylate reductase/hydroxypyruvate reductase BE728720 9380 1.5
ACLY ATP citrate lyase BI869432 47 1.5
Lipid/sterol
RODH 3-Hydroxysteroid epimerase AF223225 8630 9.5
FACL3 Fatty acid –coenzyme A ligase, long-chain 3 AK023191 2181 3.0
TMEPAI Transmembrane, prostate androgen– induced RNA NM_199170 56937 2.6 AR
PPAP2A Phosphatidic acid phosphatase type 2A CR617429 8611 2.5
EBP Emopamil-binding protein (sterol isomerase) CN395741 10682 2.2 AR
DHCR24 24-Dehydrocholesterol reductase BC011669 1718 2.1 AR
PIGF Phosphatidylinositol glycan, class F BQ006858 5281 2.1
CERK Ceramide kinase NM_182661 64781 1.5
Protein
HMGCS2 3-Hydroxy-3-methylglutaryl – coenzyme A synthase 2 NM_005518 3158 2.9 AR
MME Membrane metalloendopeptidase AL833459 4311 2.3
KLK3 Kallikrein 3, (PSA) CF140712 354 2.3 AR, IFN
ODC1 Ornithine decarboxylase 1 BU153337 4953 1.9 AR
GOT2 Glutamic –oxaloacetic transaminase 2, mitochondrial AK098313 2806 1.7
ACY1L2 Aminoacylase 1– like 2 AK094996 135293 1.7
GBDR1 Putative glioblastoma cell differentiation-related BC004967 10422 1.7
ADAM23 A disintegrin and metalloproteinase domain 23 AF052115 8745 1.7
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 BX538027 220 1.6 AR
KLK2 Kallikrein 2, prostatic NM_005551 3817 1.6 AR
GOT1 Glutamic –oxaloacetic transaminase 1, soluble CR616132 2805 1.5 AR
Other
NDUFS3 NADH dehydrogenase (ubiquinone) Fe–S protein 3,
30 kDa
AF100743 4722 2.1
ACPP Acid phosphatase, prostate AI547266 55 2.1 AR
DTYMK Deoxythymidylate kinase AA427388 1841 2.1
DCXR Dicarbonyl/L-xylulose reductase BM795570 51181 1.6
RRM1 Ribonucleotide reductase M1 polypeptide AK122695 6240 1.6
AK3 Adenylate kinase 3 AW014145 205 1.6
NME1 Nonmetastatic cells 1, protein (NM23A) NM_000269 4830 1.6 E2
Proliferation/differentiation/apoptosis
CCDC5 Coiled coil domain–containing 5 AI142429 115106 2.0
TPT1 Tumor protein, translationally controlled 1 AU119000 7178 1.7
MAD2L1 MAD2 mitotic arrest deficient – like 1 BC005945 4085 1.6
PCNA Proliferating cell nuclear antigen AA953221 5111 1.6
CCNG2 Cyclin G2 CR598707 901 1.6
MCM3 MCM3 minichromosome maintenance-deficient 3 BQ213935 4172 1.5
Signal transduction
FKBP5 FK506-binding protein 5 BU618502 2289 2.7 AR
RACGAP1 Rac GTPase–activating protein 1 AB040911 29127 2.2
STMN1 Stathmin 1/oncoprotein 18 BM543057 3925 2.0
CAMKK2 Calcium/calmodulin –dependent protein kinase kinase 2, b NM_006549 10645 2.0 AR
MAP2K1 Mitogen-activated protein kinase kinase 1 L05624 5604 1.9 IFN
RAB27A RAB27A, member RAS oncogene family U38654 5873 1.9
GNB2L1 Guanine nucleotide–binding protein (G protein), b
polypeptide 2– like 1
BE300778 10399 1.8
MAP2K4 Mitogen-activated protein kinase kinase 4 NM_003010 6416 1.7
SLC9A3R2 Solute carrier family 9, isoform 3 regulatory factor 2 BU540416 9351 1.7
TM4SF3 Transmembrane 4 superfamily member 3 NM_004616 7103 1.6
APPBP1 Amyloid b precursor protein–binding protein 1, 59 kDa BC041323 8883 1.6
CCL2 Chemokine (C–C motif) ligand 2 BU532858 6347 1.6
RAN RAN, member RAS oncogene family BG775164 5901 1.5
Structure/adhesion/motility
DKFZP761D0211 Hypothetical protein DKFZp761D0211 CR619764 83986 2.1
COL1A1 Collagen, type I, a1 CV799740 1277 2.1
HMMR Hyaluronan-mediated motility receptor CR601287 3161 2.0
COL2A1 Collagen, type II, a1 CX119275 1280 1.8
TSPAN-1 Tetraspan 1 CA454232 10103 1.7
Postn periostin, osteoblast-specific factor (M. musculus) BC031449 50706 1.7
LCP1 Lymphocyte cytosolic protein 1 BC015001 3936 1.7
MYBPC1 Myosin-binding protein C, slow type BF516586 4604 1.6
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Table 3. (continued )
Human Genome
Organization Gene
Name GenBank Entrez Gene Average
Fold D
Gene List
Structure/adhesion/motility
SMOC1 SPARC-related modular calcium-binding 1 CD049369 64093 1.6
NUP93 Nucleoporin 93 kDa CR612078 9688 1.6
SYNPO2 Synaptopodin 2 AL833547 171024 1.5
CKAP5 Cytoskeleton-associated protein 5 CR623748 9793 1.5
CXCR4 Chemokine (C–X–C motif) receptor 4 BF591711 7852 1.5
Transcription regulation
NKX3-1 NK3 transcription factor – related, locus 1 BX102941 4824 3.3
SPDEF SAM-pointed domain–containing ets transcription factor BG328411 25803 2.5
TOP2A Topoisomerase (DNA) II a 170 kDa AW172827 7153 2.3 E2
CREB3L4 cAMP-responsive element –binding protein 3– like 4 AF394167 148327 2.3
H2AFZ H2A histone family, member Z BU178992 3015 1.9
RFC3 Replication factor C3, 38 kDa BC000149 5983 1.9
CDK2AP1 CDK2-associated protein 1 BU608264 8099 1.8
SMARCA2 SWI/SNF-related, matrix-associated, actin-dependent
regulator of chromatin, subfamily a, member 2
BM671383 6595 1.6
SMC2L1 SMC2 structural maintenance of chromosomes 2– like 1 BC032705 10592 1.5
SNRPB Small nuclear ribonucleoprotein polypeptides B and B1 BX363533 6628 1.5
RAD51C RAD51 homolog C AW270829 5889 1.5
HIRIP3 HIRA-interacting protein 3 NM_003609 8479 1.5
Translation–protein synthesis
GOLPH2 Golgi phosphoprotein 2 AW591201 51280 2.6
RPS2 Ribosomal protein S2 CR610190 6187 2.3
RPL4 Ribosomal protein L4 BM451248 6124 2.2
NAG Neuroblastoma-amplified protein NM_015909 51594 2.1
LOC388817 Peptidylprolyl isomerase A– like BM972350 388817 2.1
LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 BC014276 26018 2.0
EEF1A1 Eukaryotic translation elongation factor 1 a1 BC020477 1915 1.9
RPS8 Ribosomal protein S8 BQ218087 6202 1.9
RAI14 Retinoic acid– induced 14 AY317139 26064 1.8
RPL6 Ribosomal protein L6 BC071912 6128 1.8
RPL9 Ribosomal protein L9 BQ961538 6133 1.8
RPL10A Ribosomal protein L10a BQ941098 4736 1.7
EEF1B2 Eukaryotic translation elongation factor 1 b2 BX353697 1933 1.7
RPS6 Ribosomal protein S6 BG029552 6194 1.6
RPL26 Ribosomal protein L26 BG925676 6154 1.6
RPL31 Ribosomal protein L31 CN269893 6160 1.6
RPL5 Ribosomal protein L5 BM721056 6125 1.6
NACA Nascent polypeptide–associated complex a polypeptide BU164695 4666 1.6
RPL13A Ribosomal protein L13a BQ229130 23521 1.6
EIF3S6IP Eukaryotic translation initiation factor 3, subunit
6– interacting protein
BX424780 51386 1.6
RPL11 Ribosomal protein L11 BU902342 6135 1.6
RPS3A Ribosomal protein S3A BM463771 6189 1.5
RPS15A Ribosomal protein S15a CN351294 6210 1.5
RPLP0 Ribosomal protein, large, P0 BG575128 6175 1.5
RPS13 Ribosomal protein S13 CA843734 6207 1.5
RPL10 Ribosomal protein L10 BM423499 6134 1.5
RPS4X Ribosomal protein S4, X-linked BQ959684 6191 1.5
Transport
DBI Diazepam-binding inhibitor BQ940531 1622 2.5
VPS45A Vacuolar protein sorting 45A AK023170 11311 2.2
HBE1 Hemoglobin, epsilon 1 AA115963 3046 2.0
SLC39A6 Solute carrier family 39, member 6 BC008317 25800 1.7
RAB3B RAB3B, member RAS oncogene family BF792558 5865 1.7
KPNA2 Karyopherin a2 U09559 3838 1.6
TOMM40 Translocase of outer mitochondrial membrane 40 homolog BQ883428 10452 1.6
SLC16A1 Solute carrier family 16, member 1 AK000641 6566 1.6 AR
SLC25A3 Solute carrier family 25, member 3 BC068067 5250 1.5
ATP5B ATP synthase, H+-transporting, mitochondrial F1
complex, b polypeptide
CR591449 506 1.5
Other/unknown
KIAA0114 KIAA0114 gene product BI850303 57291 2.3
BRP44 Brain protein 44 BQ287816 25874 2.2
THAP5 THAP domain –containing 5 NM_182529 168451 2.0
HN1 Hematological and neurological expressed 1 CN363269 51155 2.0
KIAA0460 KIAA0460 protein AB007929 23248 2.0
PRAC Small nuclear protein PRAC BU942850 84366 1.8
SURF4 Surfeit 4 CR602588 6836 1.7
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ER Localization and DNA Binding
ERb (55 kDa) was detected by Western blot analysis in
nuclear extracts from—but not in the cytoplasm of—LuCaP
35V and E2-treated LuCaP 35V (Figure 5A). E2 treatment
increased levels of ERb in the nucleus by approximately
30%. Using EMSA, we showed that ERb in the nucleus is
able to bind to DNA. E2 treatment slightly increased levels of
ERb/DNA complexes (Figure 5B). The specificity of the inter-
action was demonstrated by the disappearance of the spe-
cific band in control reactions with a mutated ERE (xERE).
Determination of E2-Mediated Alterations in Tumor Gene
Expression by qRT-PCR
We performed qRT-PCR analysis to confirm the cDNA
microarray results for selected genes of potential biologic
importance. All messageswhose expressionwas determined
to be upregulated by cDNA array analysis were also in-
creased by qRT-PCR in E2-treated LuCaP 35V (Figure 6).
We next examined whether immune response– related
genes found to be upregulated by E2 treatment of LuCaP
35V xenografts were also altered by E2 treatment in other
CaP xenografts. In LuCaP 58, the patterns of E2 alteration
in the expression of these genes were similar to those in
LuCaP 35V. In contrast, in LuCaP 49 (a neuroendocrine
CaP xenograft whose growth suppression was less pro-
nounced), the expression of evaluated genes was minimally
altered (Figure 6). LuCaP 23.1 regressed almost completely
after E2 treatment, and, unfortunately, there was insufficient
tissue remaining for analysis. Gene expression changes in
LuCaP 35 tumors treated with E2 or DES after castration
were also evaluated. We found that the expression of
genes related to immune regulation was altered by E2 and
DES treatment, as in LuCaP 35V tumors. We continued to
examine tumor gene expression levels after expiration of
the E2 pellets and found that levels of E2-induced mes-
sages decreased, indicating dependence on the presence
of E2 (Figure 7).
Discussion
Several studies dating back to the 1980s have suggested
that mechanisms other than androgen suppression may be
involved in the estrogen-mediated inhibition of CaP growth.
Estrogens appear to be slightly more effective in treating CaP
than other means of androgen suppression [4]. Compounds
with estrogenic activity are capable of exerting direct cyto-
toxic effects on androgen-independent CaP cells in vitro
[19–23]. Our data, obtained from the androgen-deficient
environment of female mice [24] and from the present work,
show that estrogens have powerful growth-inhibitory effects
on CaP in vivo.
In the present study, we have shown that E2 and DES both
inhibit the growth of androgen-independent CaP tumors in
the androgen-depleted environment of castrated male
mice. These data clearly demonstrate that E2 exhibits effects
on CaP cells that are unrelated to the suppression of the
hypothalamic–hypophyseal axis and the subsequent de-
crease in testosterone. This novel observation prompted us
to characterize the effects of E2 on androgen-independent
CaP at the molecular level by profiling transcript alterations.
Although many of the genes differentially regulated by estro-
gen in this system are of unclear significance, others have
quite plausible roles in the observed growth inhibition on the
basis of their established functions. Among these are genes
Figure 4. Enrichment plot of gene signatures in the E2-treated LuCaP 35V
data set. The plots show the locations of the IFN (A), androgen (B), and
estrogen (C) signature genes in the gene set ranked by the E2 phenotype. The
running enrichment score (RES), as a function of position in the gene list, is
shown. The signal-to-noise ranks of all 2584 genes in the gene set are shown,
with low ranks indicating genes upregulated by E2 treatment and with high
ranks indicating genes downregulated by E2 treatment. IFN signature genes
are clearly overrepresented on the left side of the gene list, representing their
enrichment in the genes significantly upregulated by E2 treatment (FDR =
11.0%). Androgen signature genes are present on both sides of the gene list,
representing their enrichment in the genes significantly downregulated and
upregulated by E2 treatment (FDR = 21.3%). Estrogen signature genes are
also clustered on both ends of the ranked list, representing upregulation and
downregulation by E2 treatment (FDR = 54.5%).
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involved in signal transduction, cellular metabolism, and the
control of transcription and translation. We also observed
substantial changes in genes that function to regulate immune
responses—a mechanism that may contribute to tumor
growth–inhibitory effects resulting from estrogen treatment.
Among immune response–related genes altered by E2
treatment in CaP are those modulating cellular responses to
IFNs. This group was found to be significantly enriched in the
set of genes upregulated by E2 when tested by GSEA using
an independently generated list of IFN-regulated genes. The
increased expression of IFN-regulated genes is of particular
interest due to the direct antitumor activities reported for
these cytokines [43–50]. Our results are in keeping with the
results on the upregulation of IFN-regulated genes in LNCaP
CaP cells following exposure to the estrogenic herbal prep-
aration PC-SPES [51] and the induction of IFNg-regulated
genes after E2 treatment in other tissues [52]. In addition,
tamoxifen has been shown to enhance IFN-regulated gene
expression in breast cancer cells [53]. Specifically, IRF1,
whose expression was increased three-fold by E2 (qRT-
PCR data), has been described as a negative regulator of
proliferation [54] and has exhibited tumor-suppressor ac-
tivities in breast cancer cells [55]. These published observa-
tions and our results are consistent with a model in which IFN
and genes regulated by IFN modulate a component of the
growth-inhibitory activity of E2 toward androgen-independent
CaP cells.
E2 treatment significantly increased the expression of
several MHC class I/II transcripts in the androgen-indepen-
dent LuCaP 35V xenograft. Similarly, the upregulation of
MHC class I transcripts has been observed in LNCaP cells
on PC-SPES exposure [51]. MHC class I molecules are ex-
pressed in most human cells and play a pivotal role in the
immune response to viruses and tumor cells. Tumor cells
often evolve mechanisms to modulate or escape immune
surveillance through the downregulation of MHC class I
molecules [56–60]. IFNg treatment, like E2 treatment in our
studies, has been reported to upregulate the expression of
MHC class I/II molecules in CaP cell lines [44,58,59]. Accord-
ing to this evidence, the treatment of advanced CaP pa-
tients with E2 might result not only in direct inhibitory effects
but also in the stimulation of T-cell attack on tumors by the
upregulation of MHC proteins. Such a mechanism could not
be directly tested in our study, which employed immune-
compromised SCID mice, but it represents an independent
potential benefit of E2 treatment that could be exploited in the
context of clinical therapies employing vaccine or other
immunomodulatory treatment strategies.
DES has been reported to be ineffective in inhibiting
LuCaP 35 growth in intact male mice [61]. We also observed
that E2 did not inhibit LuCaP 35 growth in intact male mice
(data not shown). These results suggest that phenotypic
changes caused by E2 treatment are specific to an androgen-
depleted environment. In contrast to our E2 data, raloxifene,
an estrogen receptor antagonist, has been reported to in-
hibit the growth of both androgen-sensitive and androgen-
independent CaP in vitro [20,21]. Raloxifene has also been
reported to delay CaP development in probasin/SV40
Tantigen transgenic rats [62] and to inhibit the growth of both
androgen-sensitive and androgen-independent variants of
the CWR22 CaP xenograft [63]. Thus, the emerging picture
of estrogenic effects on androgen-independent CaP is com-
plex, possibly involving multiple mechanisms, some of which
may involve signal transduction by estrogen receptors. Ad-
ditional preclinical studies are clearly warranted to deconvo-
lute these effects.
Figure 5. Measurements of ER expression in LuCaP 35V xenografts. LuCaP 35 cells were isolated from tumor bits and treated in vitro with E2 for 4 hours. (A)
ER was detected in nuclear extracts, whereas cytoplasmic protein extracts were negative for ER. E2 increased the amount of ER in the nucleus byf1.5-fold.
(B) Nuclear extracts of LuCaP 35V and LuCaP 35V that were treated with E2 in vitro for 4 hours were used for EMSA. ER/DNA complexes were detected in both
samples, with increased amounts in E2-treated LuCaP 35V. The specificity of binding was demonstrated by competition with an xERE sequence.
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A potential mechanismwhereby E2may cause alterations
of the gene expression profile we have observed in CaP
cells is signal transduction through ERb expressed by CaP
cells. It has been reported that ERb expression declines as
CaP develops in the prostate gland, but we and others have
shown that it reappears in lymph node and bone metastases
[27]. This apparent discrepancy is probably explained by the
recent findings of the reversible epigenetic regulation of ERb
in CaP metastases [64]. We have shown previously that the
xenografts used in this study express ERb [24]. In the present
study, we have shown that the androgen-independent
LuCaP 35V xenograft expresses ERb protein in a form
that is capable of DNA binding, and that ERb levels in
nuclei and DNA-binding activities are increased on E2
treatment. Together, these results suggest the possibility that
E2-mediated inhibition is, at least in part, transduced by ERb
signaling, but further studies are required to demonstrate
direct involvement of ERb with these phenomena. One
important aspect of preclinical testing involves the use of
models that mimic the disease in patients. If it is eventually
found that E2 is beneficial in advanced CaP and that
the effects are mediated by ERb, then evaluation of the
expression of ERb in patient tumors could prove to be
valuable in treatment decisions, as is the case with HER2/
Neu and herceptin treatment today.
The E2-inhibitory effects observed cannot be caused
by suppression of the hypothalamic–hypophyseal axis re-
duction in testosterone levels because the tumors were
grown in castrated male mice. However, our data do suggest
that AR signaling may be at least partially involved in the
inhibitory effects observed. All of the xenografts, except
LuCaP 49, express AR (data not shown), and the inhibition
of LuCaP 49 by E2 was less pronounced than in other
xenografts. Moreover, GSEA showed that genes in an inde-
pendently generated list of genes downregulated by andro-
gen deprivation were significantly enriched in the phenotype
of E2-treated LuCaP 35V, with about half of the genes
downregulated by E2 and half upregulated by E2. For ex-
ample, the expression of heat shock protein 70, which is
downregulated after castration [65], was upregulated by E2
treatment (Table 2). These results illustrate the complexity of
these signaling networks. Further studies are needed to
delineate the action of E2 on AR signaling in CaP cells.
The results reported here support the multifaceted roles
of estrogen in the inhibition of androgen-independent CaP
growth. These observations extend the traditional view of
estrogen activity beyond the suppression of circulating con-
centrations of androgens. Direct cellular effects and the
modulation of immune responses represent additional po-
tential mechanisms that could be further exploited through
combination therapies. Given that estrogens also decrease
bone lysis caused by androgen suppression [66] and may
ameliorate cognitive side effects associated with low tes-
tosterone [67], the use of estrogens should be considered
as a viable first-line treatment strategy for androgen-
independent CaP.
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